Myotonic Disorders: Clinical Trials

20 trials for Myotonic Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 6 recruiting, 2 enrolling by invitation, 2 unknown. 20 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 320Completed 8, Recruiting 6, Enrolling by invitation 2, Unknown 2, Terminated 1, Withdrawn 1
Phase 24Completed 3, Recruiting 1

Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
Phase 3RecruitingAvidity Biosciences, Inc.702026-09-012026-11-10
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Zeleciment Rostudirsen (DYNE-251), Placebo - Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne
Phase 3RecruitingDyne Therapeutics902026-06-012026-05-27
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
zeleciment basivarsen (DYNE-101), Placebo - Myotonic Dystrophy Type 1 (DM1), DM1
Phase 3RecruitingDyne Therapeutics1502026-05-142026-11-13
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
Mexiletine granules for prolonged-release oral suspension - Myotonic Dystrophy
Phase 3Enrolling by invitationLupin Ltd.1762025-09-122026-01-26
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Del-desiran (AOC 1001) - Myotonic Dystrophy Type 1, DM1
Phase 3Enrolling by invitationAvidity Biosciences, Inc.1992025-06-262026-08-19
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Mexiletine granules for prolonged-release oral suspension, Placebo - Myotonic Dystrophy
Phase 3RecruitingLupin Ltd.1762025-02-132026-09-24
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Treatment taken - Steinert's Disease, Myotonic Dystrophy 1
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1422024-11-292025-11-24
Global Study of Del-desiran for the Treatment of DM1
AOC 1001 (del-desiran), Placebo - DM1, Myotonic Dystrophy
Phase 3CompletedAvidity Biosciences, Inc.1592024-05-302026-09-01
Home-based Training and Supplementation in DM1 Patients
Mult-ingredient supplement, Placebo, Concurrent exercise training - Myotonic Dystrophy 1
Phase 3UnknownMcMaster University602024-01-012023-10-19
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
Mexiletine 167 mg, Placebo - Myotonic Dystrophy Type 1 and Type 2
Phase 3WithdrawnLupin Ltd.2021-09-032024-05-06
Open Label Study in Adolescents and Children With Myotonic Disorders
Mexiletine - Myotonic Dystrophy
Phase 3CompletedLupin Ltd.122021-09-032024-11-25
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Tideglusib - Congenital Myotonic Dystrophy
Phase 2 / Phase 3RecruitingAMO Pharma Limited762021-08-232025-05-28
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Tideglusib, Placebo - Congenital Myotonic Dystrophy
Phase 2 / Phase 3CompletedAMO Pharma Limited562021-03-032025-10-08
Lamotrigine as Treatment of Myotonia
Lamotrigine, Placebo - Dystrophia Myotonica Type 1, Myotonia Congenita
Phase 3CompletedGrete Andersen, MD272013-11-012016-04-25
Mexiletine and Non Dystrophic Myotonias
Mexiletine, placebo - Non-dystrophic Myotonias, Paramyotonia Congenita
Phase 3CompletedAssistance Publique - Hôpitaux de Paris242011-06-012015-01-13
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
Bilevel pressure ventilator - Myopathy, Muscular Weakness
Phase 3UnknownAssistance Publique - Hôpitaux de Paris772010-10-012017-11-20
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
mechanical insufflation - exsufflation, Standard respiratory physiotherapy - Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris142009-06-012015-05-28
Methylphenidate in Myotonic Dystrophy Type 1
Methylphenidate, Placebo - Dystrophia Myotonica 1
Phase 2 / Phase 3CompletedLaval University282008-06-012011-08-23
Efficacy and Safety of DHEA for Myotonic Dystrophy
dehydroepiandrosterone 100 and 400 mg - Myotonic Dystrophy
Phase 2 / Phase 3CompletedUniversity of Versailles752004-11-012010-04-06
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
dichlorphenamide - Paralysis, Hyperkalemic Periodic, Hypokalemic Periodic Paralysis
Phase 3CompletedNational Center for Research Resources (NCRR)641992-06-012005-06-24

Narrower conditions

Myotonic Dystrophy (17)  ·  Myotonia (4)  ·  Muscular Dystrophy, Duchenne (3)  ·  Myotonia Congenita (3)  ·  Neuromuscular Diseases (3)  ·  Disorders of Excessive Somnolence (2)  ·  Genetic Diseases, Inborn (2)  ·  Muscular Diseases (2)  ·  Muscular Dystrophies (2)  ·  Paralysis, Hyperkalemic Periodic (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, X-Linked (1)  ·  Hypokalemic Periodic Paralysis (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19)  ·  Heredodegenerative Disorders, Nervous System (19)  ·  Musculoskeletal Diseases (19)  ·  Nervous System Diseases (19)  ·  Neurodegenerative Diseases (19)  ·  Genetic Diseases, Inborn (18)  ·  Muscular Diseases (18)  ·  Muscular Disorders, Atrophic (17)  ·  Neuromuscular Diseases (17)  ·  Muscular Dystrophies (16)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (6)  ·  Neurologic Manifestations (5)  ·  Neuromuscular Manifestations (5)

Interventions

Mexiletine (3)  ·  tideglusib (2)  ·  Dichlorphenamide (1)  ·  Lamotrigine (1)  ·  Methylphenidate (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (4)  ·  Lupin Ltd. (4)  ·  Avidity Biosciences, Inc. (3)  ·  AMO Pharma Limited (2)  ·  Dyne Therapeutics (2)  ·  Grete Andersen, MD (1)  ·  Laval University (1)  ·  McMaster University (1)  ·  National Center for Research Resources (NCRR) (1)  ·  University of Versailles (1)

Countries

France (10)  ·  Canada (7)  ·  United Kingdom (7)  ·  Denmark (6)  ·  Germany (6)  ·  Italy (6)  ·  Spain (6)  ·  United States (6)  ·  Australia (4)  ·  Belgium (4)  ·  Netherlands (4)  ·  Japan (3)  ·  New Zealand (3)  ·  Poland (1)

Top investigators

Bertrand Fontaine, MD, PhD (1)  ·  Grete Andersen, MD (1)  ·  Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM (1)  ·  Jack J Puymirat, MD (1)  ·  Jerry R. Mendell (1)  ·  Joseph P Horrigan, MD (1)  ·  Savine Vicart, MD (1)

Results publications

PMID 18678823, PMID 22578232, PMID 39555632

NIH funding

2025 (2), 2016 (1), 2023 (1)